Hans Henrik D. Parving

Hans Henrik D. Parving's AcademicInfluence.com Rankings

Philosophy

#5426

Historical Rank

Logic

#1750

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Hans Henrik D. Parving's Degrees

Doctorate Medicine University of Copenhagen
PhD Medicine University of Copenhagen

Why Is Hans Henrik D. Parving Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hans Henrik D. Parving's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (2001) (5071)
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. (2003) (4290)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. (2001) (3174)
Effect of a multifactorial intervention on mortality in type 2 diabetes. (2008) (3152)
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. (2002) (1883)
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. (2009) (1786)
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. (2012) (1133)
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. (2009) (1106)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004) (956)
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study (1999) (946)
EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHY (1983) (912)
Aliskiren combined with losartan in type 2 diabetes and nephropathy. (2008) (841)
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. (2013) (796)
Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004) (746)
Nephropathy in diabetes. (2004) (698)
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial (2010) (678)
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. (2002) (672)
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. (2011) (645)
Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. (1982) (613)
Prevention of diabetic renal disease with special reference to microalbuminuria (1995) (567)
Effect of antihypertensive treatment on kidney function in diabetic nephropathy. (1987) (563)
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). (2003) (495)
Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. (1991) (482)
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. (2006) (479)
Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes (1988) (461)
Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study (1996) (458)
Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. (1992) (443)
Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study (1997) (428)
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials (2008) (425)
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial (2008) (417)
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study (2004) (410)
Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM (1995) (379)
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. (2003) (373)
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial (2016) (369)
Progression of nephropathy in type 2 diabetic patients. (2004) (355)
Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. (1988) (347)
Microalbuminuria as an early marker for cardiovascular disease. (2006) (345)
Is diabetic nephropathy an inherited complication? (1992) (330)
Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. (1986) (312)
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. (2009) (311)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. (1994) (310)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (2019) (306)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. (2007) (305)
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. (2000) (296)
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. (2002) (291)
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. (2011) (287)
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. (2005) (282)
Progression of diabetic nephropathy. (2001) (255)
Transcapillary Escape Rate of Albumin and Plasma Volume in Essential Hypertension (1973) (250)
New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes (2012) (250)
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. (2003) (248)
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. (2005) (246)
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. (2002) (245)
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. (2003) (240)
Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications (2005) (237)
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. (2009) (236)
Diabetic nephropathy: prevention and treatment. (2001) (226)
Beneficial impact of spironolactone in diabetic nephropathy. (2005) (219)
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. (2014) (217)
Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. (2002) (215)
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. (2003) (215)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) (214)
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. (2004) (214)
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. (2012) (213)
Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes (2011) (213)
Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate (2004) (212)
Prognosis in diabetic nephropathy. (1989) (206)
Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin I–Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients (1995) (206)
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. (2006) (203)
Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. (2004) (201)
Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. (1989) (196)
Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V (1994) (195)
Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria (1999) (189)
Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? (2002) (183)
Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy (1997) (181)
Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial (2011) (174)
Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. (2006) (167)
Evidence for Diabetic Encephalopathy (1991) (164)
Comparison of different measures of urinary protein excretion for prediction of renal events. (2010) (163)
Glomerular Structure and Function in Diabetic Nephropathy: Early to Advanced Stages (1990) (162)
Vitamin D Levels and Mortality in Type 2 Diabetes (2010) (159)
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria (2009) (153)
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. (2006) (152)
Renoprotection in diabetes: genetic and non-genetic risk factors and treatment (1998) (150)
Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients (1993) (149)
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus (2007) (147)
Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. (1999) (145)
Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. (2000) (144)
Unchanged Incidence of Diabetic Nephropathy in IDDM Patients (1995) (144)
Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes (2008) (137)
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. (2008) (136)
The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (2000) (135)
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. (2008) (135)
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. (2002) (134)
Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. (2005) (131)
Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. (1999) (130)
Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes (2009) (126)
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. (2011) (125)
Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. (2000) (125)
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. (2011) (124)
Subclinical Coronary and Aortic Atherosclerosis Detected by Magnetic Resonance Imaging in Type 1 Diabetes With and Without Diabetic Nephropathy (2006) (124)
Association between Mannose‐Binding Lectin and Vascular Complications in Type 1 Diabetes (2004) (124)
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals (2010) (123)
Excess mortality associated with diuretic therapy in diabetes mellitus. (1992) (122)
Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes (2011) (120)
Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years (2008) (120)
Neutrophil Gelatinase‐Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross‐sectional study and the effects of lisinopril (2010) (119)
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. (2005) (118)
Double‐blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients (2001) (117)
Diabetic Nephropathy and Arterial Hypertension: The Effect of Antihypertensive Treatment (1983) (117)
Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes (2010) (116)
Expression, localization, and function of the thioredoxin system in diabetic nephropathy. (2009) (115)
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. (2005) (114)
Association between mannose-binding lectin and vascular complications in type 1 diabetes. (2004) (114)
Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. (2006) (114)
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. (1998) (112)
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. (2015) (112)
Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study (2011) (111)
Pregnancy and progression of diabetic nephropathy (2002) (110)
Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. (1993) (109)
Initiation and progression of diabetic nephropathy. (1996) (109)
Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy (2010) (107)
Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients (2010) (107)
Glomerular structure and function in proteinuric Type 2 (non-insulin-dependent) diabetic patients (1993) (106)
Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria (2004) (104)
A Nation‐wide Cross‐sectional Study of Urinary Albumin Excretion Rate, Arterial Blood Pressure and Blood Glucose Control in Danish Children with Type 1 Diabetes Mellitus (1990) (104)
Reduction in albuminuria predicts diminished progression in diabetic nephropathy. (1994) (102)
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study (2007) (102)
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment (1994) (102)
QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes (2000) (101)
Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. (1997) (101)
Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes (2006) (101)
Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. (2001) (101)
Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. (2001) (100)
A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy (1981) (99)
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. (1995) (97)
Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy? (1995) (96)
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. (2011) (96)
Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. (2003) (96)
Progression of diabetic nephropathy in normotensive type 1 diabetic patients. (1999) (94)
On the Mechanisms of Blunted Nocturnal Decline in Arterial Blood Pressure in NIDDM Patients With Diabetic Nephropathy (1995) (94)
Endothelial dysfunction and low‐grade inflammation and the progression of retinopathy in Type 2 diabetes (2007) (93)
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and re (2004) (92)
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. (2005) (92)
The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy (1993) (91)
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. (2008) (91)
A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes (2010) (90)
Impact of Blood Pressure and Antihypertensive Treatment on Incipient and Overt Nephropathy, Retinopathy, and Endothelial Permeability in Diabetes Mellitus (1991) (89)
Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. (1998) (88)
Analysis of 14 Candidate Genes for Diabetic Nephropathy on Chromosome 3q in European Populations (2006) (88)
Glomerular permselectivity in early stages of overt diabetic nephropathy. (2000) (88)
Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. (2014) (88)
Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. (1995) (87)
Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. (2005) (86)
Evolving strategies for renoprotection: diabetic nephropathy (2001) (86)
Microalbuminuria: a parameter that has changed diabetes care. (2015) (86)
Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. (2012) (86)
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. (1999) (86)
Optimal dose of losartan for renoprotection in diabetic nephropathy. (2002) (85)
Mannose-binding lectin and mortality in type 2 diabetes. (2006) (85)
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. (2000) (85)
The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality (2007) (84)
Telomere length predicts all-cause mortality in patients with type 1 diabetes (2009) (83)
Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study (2008) (83)
Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. (2017) (82)
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study (2008) (81)
DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. (2008) (81)
Effects of insulin on kidney function and sodium excretion in healthy subjects (1989) (80)
Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience (2011) (80)
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. (2008) (79)
Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. (1998) (79)
Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (2013) (79)
Raised Serum Sialic Acid Concentration in NIDDM Patients With and Without Diabetic Nephropathy (1996) (79)
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. (2011) (77)
Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria (2006) (76)
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. (2000) (76)
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. (2008) (76)
Diabetic nephropathy and arterial hypertension (2004) (75)
Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy (1996) (75)
Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. (2005) (75)
Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. (2003) (74)
Anaemia in diabetes: is there a rationale to TREAT? (2006) (74)
Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. (2007) (74)
Angiotensinogen Gene Polymorphisms in IDDM Patients With Diabetic Nephropathy (1996) (73)
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease (2019) (73)
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study (2012) (73)
Impact of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy (1994) (72)
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). (2011) (72)
Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. (2001) (71)
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study (2016) (70)
Smoking and progression of diabetic nephropathy in type 1 diabetes. (2003) (70)
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria (2010) (70)
Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. (2002) (70)
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). (2009) (69)
Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy (2008) (68)
Serum uric acid as a new player in the development of diabetic nephropathy. (2011) (68)
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) (2012) (68)
Fish Oil in Diabetic Nephropathy (1996) (67)
Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. (2014) (67)
Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. (1999) (67)
Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes (2016) (67)
Remission of nephrotic-range albuminuria in type 1 diabetic patients. (2001) (67)
Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition (2009) (67)
Effects of Long‐term Antihypertensive Treatment on Kidney Function in Diabetic Nephropathy (1985) (65)
Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria (2011) (65)
Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors (2014) (64)
Glomerular hyperfiltration in microalbuminuric NIDDM patients (1996) (64)
Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study (2018) (63)
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2009) (63)
Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes (2019) (63)
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy (1995) (63)
Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. (2003) (62)
Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment (1997) (62)
The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics (2005) (62)
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? (2003) (62)
Early changes in diabetic retinopathy: Capillary loss and blood‐retina barrier permeability in relation to metabolic control (1994) (61)
Microalbuminuria in essential hypertension and diabetes mellitus (1996) (61)
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy (2018) (60)
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. (2000) (60)
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2010) (60)
Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. (2001) (60)
A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes (2008) (60)
Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy (1984) (60)
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. (2000) (60)
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). (2014) (59)
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy (1992) (59)
Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy (2004) (59)
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. (2011) (59)
Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy (2004) (59)
Improved prognosis of diabetic nephropathy in type 1 diabetes. (2015) (59)
Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy (2010) (59)
Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. (1996) (58)
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. (2004) (58)
Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients (2005) (58)
Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria (2003) (57)
A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy (1988) (57)
Prevalence of microalbuminuria in children with Type 1 (insulin-dependent) diabetes mellitus (1986) (56)
Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy (1996) (56)
Genetic Examination of SETD7 and SUV39H1/H2 Methyltransferases and the Risk of Diabetes Complications in Patients With Type 1 Diabetes (2011) (56)
Osteoprotegerin and Mortality in Type 2 Diabetic Patients (2010) (56)
Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. (1999) (55)
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial (2016) (55)
Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. (2016) (54)
[The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. (2003) (54)
Diabetes and end stage renal disease (2000) (54)
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study (2017) (54)
Increased microvascular permeability to plasma proteins in short- and long-term juvenile diabetics. (1976) (54)
Short stature and diabetic nephropathy (1995) (53)
G/T Substitution in Intron 1 of the UNC13B Gene Is Associated With Increased Risk of Nephropathy in Patients With Type 1 Diabetes (2008) (52)
Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate (2011) (52)
Insulin analogues and severe hypoglycaemia in type 1 diabetes. (2012) (52)
Left Ventricular Hypertrophy in Non‐insulin‐dependent Diabetic Patients With and Without Diabetic Nephropathy (1997) (52)
Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. (2018) (52)
Effect of a Multifactorial Intervention on Mortality in Type II Diabetes (2008) (51)
Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. (2005) (50)
Microalbuminuria as an early indicator of osteopenia in male insulin‐dependent diabetic patients (1997) (49)
Reduced Albuminuria During Early and Aggressive Antihypertensive Treatment of Insulin-dependent Diabetic Patients with Diabetic Nephropathy (1981) (49)
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study (2017) (48)
Diurnal variations of glomerular filtration rate and albuminuria in diabetic nephropathy. (2002) (48)
Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. (1996) (48)
The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1 (2013) (47)
Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. (2006) (46)
Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. (2000) (46)
Does microalbuminuria predict diabetic nephropathy? (2002) (46)
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. (2005) (45)
Increased Metabolic Turnover Rate and Transcapillary Escape Rate of Albumin in Essential Hypertension (1974) (45)
Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review (2016) (45)
SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes (2014) (45)
Elevated Urinary Prostaglandin Excretion and the Effect of Indomethacin on Renal Function in Incipient Diabetic Nephropathy (1988) (44)
Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy (2002) (44)
Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. (1999) (44)
Prevalence of hyperglycaemia and undiagnosed diabetes mellitus in patients with acute myocardial infarction. (2009) (44)
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. (2015) (44)
Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy (1995) (43)
Effects of hyperglycaemia on kidney function, atrial natriuretic factor and plasma renin in patients with insulin-dependent diabetes mellitus. (1991) (42)
Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes (2012) (42)
Reduced Urinary Excretion of Epidermal Growth Factor in Incipient and Overt Diabetic Nephropathy (1989) (42)
Diabetic microvascular complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients. (2001) (42)
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study (2005) (42)
Red cell Na+/Li+ countertransport in non-insulin-dependent diabetics with diabetic nephropathy. (1991) (41)
Effect of insulin on renal sodium handling in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance (1991) (41)
PGC-1α Gly482Ser Polymorphism Associates With Hypertension Among Danish Whites (2005) (41)
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes (2009) (41)
CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients. (2000) (40)
Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci (2015) (39)
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial (2009) (39)
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? (2002) (39)
Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial (2007) (39)
On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy. (1989) (39)
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. (2004) (38)
Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria (2018) (38)
Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. (1998) (38)
Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. (2008) (38)
The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics (2009) (38)
European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy. (2007) (38)
White Coat Hypertension in NIDDM Patients With and Without Incipient and Overt Diabetic Nephropathy (1997) (37)
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2011) (37)
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria (2017) (36)
Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes (2015) (36)
Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive Type 1 (insulin-dependent) diabetic patients with background retinopathy (1989) (36)
High YKL-40 levels predict mortality in patients with type 2 diabetes. (2012) (36)
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial (2010) (36)
Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control (2008) (36)
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. (2008) (36)
Pathophysiological aspects of edema formation in diabetic nephropathy. (1990) (36)
Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate (2017) (35)
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial (2008) (35)
Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy (1999) (35)
Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. (1997) (34)
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. (2016) (34)
Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? (1999) (34)
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials (2011) (34)
Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. (2005) (34)
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers (2016) (33)
Remission and regression of diabetic nephropathy (2004) (33)
Effects of indomethacin on kidney function in Type 1 (insulin-dependent) diabetic patients with nephropathy (1987) (32)
Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone. (2005) (32)
Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function (2010) (32)
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. (2015) (32)
The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria. (1996) (31)
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy (2004) (31)
Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity (2009) (31)
Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria (2018) (31)
Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study (2012) (30)
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. (2003) (30)
Increased blood pressure and erythrocyte sodium/lithium countertransport activity are not inherited in diabetic nephropathy (1990) (30)
Relationship Between Blood Pressure and Urinary Albumin Excretion Rate in Young Danish Type 1 Diabetic Patients: Comparison to Non‐diabetic Children (1994) (30)
Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. (2000) (30)
Total plasma homocysteine is associated with hypertension in Type I diabetic patients (2002) (30)
Diabetic nephropathy. (2003) (30)
Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. (2003) (30)
Microalbuminuria and obesity: impact on cardiovascular disease and mortality (2009) (30)
IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. (2015) (30)
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients (2004) (30)
Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies (2017) (30)
The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. (1990) (30)
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. (1996) (29)
Renoprotection with and without blood pressure reduction. (2005) (29)
Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. (1992) (29)
Monitoring kidney function in diabetic nephropathy (1994) (29)
SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes (2012) (29)
Probenecid inhibition of the outward transport of fluorescein across the human blood‐retina barrier (1994) (29)
The Importance of Short‐Term Off‐Target Effects in Estimating the Long‐Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers (2014) (29)
Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. (2011) (29)
Polymorphisms in the Interleukin-1 Gene Cluster Do Not Contribute to the Genetic Susceptibility of Diabetic Nephropathy in Caucasian Patients With IDDM (1997) (29)
Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? (2013) (28)
Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients (2000) (28)
Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study (2018) (28)
Long-term prevention of diabetic nephropathy: an audit (2008) (28)
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. (2003) (28)
An Extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) System for Grading of Diabetic Macular Edema in the Astemizole Retinopathy Trial (2006) (27)
Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. (2001) (27)
NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis (2011) (27)
Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? (2006) (27)
Hypotensive Therapy Reduces Microvascular Albumin Leakage in Insulin‐dependent Diabetic Patients with Nephropathy (1986) (27)
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. (2009) (27)
The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes. (2001) (27)
Trisomy 8 syndrome (1977) (26)
The prevalence of coeliac disease in adult Danish patients with type 1 diabetes with and without nephropathy (2005) (26)
The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. (2008) (26)
A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers (2014) (26)
Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction? (2006) (25)
A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus (2010) (25)
[Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study]. (1999) (25)
Course of glomerular filtration rate in albuminuric type 2 diabetic patients with or without diabetic glomerulopathy. (2000) (25)
PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites. (2005) (25)
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. (2015) (25)
Renal protection in diabetes: an emerging role for calcium antagonists (1996) (25)
Beneficial Impact of Ramipril on Left Ventricular Hypertrophy in Normotensive Nonalbummuric NIDDM Patients (1998) (25)
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease (2013) (24)
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. (2005) (24)
PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. (2002) (24)
Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria (2016) (23)
Plasma volume, intravascular albumin and its transcapillary escape rate in patients with extensive skin disease (1976) (23)
Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients (2018) (23)
Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus. (2011) (23)
High blood pressure is a major factor in progression of diabetic nephropathy. (1988) (23)
Quantitative studies of glomerular ultrastructure in human and experimental diabetes. (1984) (23)
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. (2001) (23)
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. (2013) (23)
Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria (2020) (23)
Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study (2014) (23)
THE BLOOD‐RETINAL BARRIER PERMEABILITY IN ESSENTIAL HYPERTENSION (1983) (22)
Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. (2013) (22)
Diabetic hypertensive patients. Is this a group in need of particular care and attention? (1999) (22)
Calcium antagonists and cardiovascular risk in diabetes. (1998) (22)
NT‐proBNP by Itself Predicts Death and Cardiovascular Events in High‐Risk Patients With Type 2 Diabetes Mellitus (2020) (22)
Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy (1993) (22)
Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. (2000) (21)
Effects of acetazolamide on kidney function in Type 1 (insulin-dependent) diabetic patients with diabetic nephropathy (1988) (21)
Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial. (2016) (21)
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. (2001) (21)
Increased Plasma Apolipoprotein(a) Levels in IDDM Patients With Diabetic Nephropathy (1996) (20)
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). (2019) (20)
Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen (1995) (20)
Urinary Neutrophil Gelatinase-Associated Lipocalin and Progression of Diabetic Nephropathy in Type 1 Diabetic Patients in a Four-Year Follow-Up Study (2010) (20)
The acute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man. (1989) (20)
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria (2012) (20)
Antihypertensive effects of double the maximum dose of valsartan in African–American patients with type 2 diabetes mellitus and albuminuria (2010) (20)
Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. (2017) (20)
Higher plasma soluble receptor for advanced glycation endproducts (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-yr follow-up study (2010) (20)
Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy (1999) (19)
Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. (2007) (19)
The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP (2012) (19)
Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort (2017) (19)
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. (2011) (19)
Elevated Placental Growth Factor (PlGF) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients with Diabetic Nephropathy (2005) (19)
Increased Left Ventricular Mass in Normotensive Type 1 Diabetic Patients With Diabetic Nephropathy (1998) (19)
Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. (2003) (18)
Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. (2018) (18)
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. (2005) (18)
NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients (2012) (18)
Blood‐retina barrier permeability in diabetes during acute ACE‐inhibition (1991) (18)
Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. (1996) (18)
Acute reduction of arterial blood pressure reduces urinary albumin excretion in Type 1 (insulin-dependent) diabetic patients with incipient nephropathy (1986) (18)
Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria. (2001) (18)
Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients (2012) (18)
Toe–brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria (2017) (18)
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria (2011) (18)
Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial. (2018) (18)
Birth weight – a risk factor for progression in diabetic nephropathy? (2003) (17)
Stable Glomerular Filtration Rate in Normotensive IDDM Patients With Stable Microalbuminuria: A 5-year prospective study (1997) (17)
Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study (2015) (17)
Direct renin inhibition in chronic kidney disease (2012) (16)
Renal protection in diabetes--an emerging role for calcium antagonists. (1996) (16)
Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy. (1998) (16)
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus (2016) (16)
Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. (1996) (16)
Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. (2004) (16)
Baseline characteristics and enrichment results from the SONAR trial (2018) (16)
Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. (1997) (15)
Effect of short‐term hyperglycaemia on haemodynamics in type 1 diabetic patients (2003) (15)
A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design (2012) (15)
Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition (2004) (15)
Pregnancy‐associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy—a prospective follow‐up study (2007) (15)
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy (2017) (15)
CYP2C9 variant modifies blood pressure‐lowering response to losartan in Type 1 diabetic patients with nephropathy (2007) (15)
Is antihypertensive treatment the same for NIDDM and IDDM patients? (1998) (15)
Evaluation of placental growth factor and soluble Fms‐like tyrosine kinase 1 as predictors of all‐cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy (2012) (15)
Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study (2019) (14)
A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women. (2011) (14)
Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus. (1992) (14)
Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia‐prone people with Type 1 diabetes (2017) (14)
The increased proximal tubular reabsorption of sodium and water is maintained in long-term insulin-dependent diabetics with early nephropathy. (1989) (14)
Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus. (1989) (14)
Dyslipidaemia and cardiovascular disease in non-insulin-dependent diabetic patient with and without diabetic nephropathy. (1994) (14)
Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus (2009) (13)
The natural course of glomerular filtration rate and arterial blood pressure in diabetic nephropathy, and the effect of antihypertensive treatment. (1981) (13)
Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. (1999) (13)
A Comparative Study of Microvascular Complications in Patients with Secondary and Type 1 Diabetes (1990) (13)
Dual renin-angiotensin system blockade and kidney disease. (2009) (13)
Relationship between blood pressure and urinary albumin excretion rate in young Danish type 1 diabetic patients: comparison to non-diabetic children. Danish Study Group of Diabetes in Childhood. (1994) (13)
Controlling hypertension in diabetes (2002) (13)
The insertion/deletion polymorphism in the angiotensin I-converting enzyme gene predicts the progression of diabetic nephropathy during ACE inhibition in insulin dependent diabetic patients (1995) (13)
Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria (2021) (13)
Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA. (1998) (13)
Effects of Short‐term Strict Metabolic Control on Kidney Function and Extracellular Fluid Volume in Incipient Diabetic Nephropathy (1989) (12)
Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes (2011) (12)
Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (2016) (12)
The Trp64Arg amino acid polymorphism of the beta3-adrenergic receptor gene does not contribute to the genetic susceptibility of diabetic microvascular complications in Caucasian type 1 diabetic patients. (1999) (12)
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial (2018) (12)
Antihypertensive treatment postpones end-stage renal failure in diabetic nephropathy. (1988) (12)
Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy (2015) (11)
Prevalence and causes of microscopic haematuria in Type 1 (insulin-dependent) diabetic patients with persistent proteinuria (1987) (11)
Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy (2011) (11)
Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type‐2 diabetes mellitus (2008) (11)
A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study (2018) (11)
Aldosterone synthase (CYP11B2) −344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients (2006) (10)
Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight (2018) (10)
Surrogate endpoints and renal protection: focus on microalbuminuria. (1997) (10)
Glomerular size-and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy (1994) (10)
Reduced transcapillary escape of albumin during acute blood pressure-lowering in Type 1 (insulin-dependent) diabetic patients with nephropathy (1985) (10)
N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk (2018) (10)
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes (2011) (10)
[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]. (2009) (10)
Angiotensin-converting enzyme inhibition in diabetic nephropathy. (1989) (10)
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. (2017) (10)
Effects of Dietary Protein on Renal Disease (1997) (9)
Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. (1998) (9)
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. (2016) (9)
Hypertension and Diabetes: the Scope of the Problem (2001) (9)
Monitoring progression of diabetic nephropathy. (1985) (9)
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. (2009) (9)
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. (2011) (9)
Preventing diabetic nephropathy: an audit (2001) (8)
Hypertension Optimal Treatment (HOT) trial (1998) (8)
Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria (2011) (8)
CD2AP is associated with end-stage renal disease in patients with type 1 diabetes (2013) (8)
The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design (2019) (8)
The History of Prevention and Treatment of Diabetic Nephropathy (2020) (8)
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension (2006) (8)
Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Running title: The tubular marker u-LFABP in type 1 diabetes (2010) (8)
Morphology of diabetic glomerulopathy and relationship to hypertension. (1989) (8)
Acquired oligonephropathy and diabetic nephropathy. (1995) (8)
Intermittent clinical proteinuria and renal function in diabetes (1986) (7)
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. (2001) (7)
Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. (2018) (7)
Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. (2016) (7)
Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. (2009) (7)
Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in PatientsWith Type 2 Diabetes andMicroalbuminuria An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy (2011) (7)
Low-protein diet and progression of renal disease in diabetic nephropathy (1990) (7)
Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus (2000) (7)
Protein restriction and renal failure in diabetes mellitus. (1991) (6)
Aldosterone synthase (CYP11B2)344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy (2006) (6)
High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. (2016) (6)
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function (2021) (6)
Lack of familial predisposition to cardiovascular disease in Type 1 (insulin-dependent) diabetic patients with nephropathy (1991) (6)
Effect of carbonic anhydrase inhibitors on glomerular filtration rate in diabetic nephropathy. (1987) (6)
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (2017) (6)
Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial (2020) (6)
Visit‐to‐visit variability of clinical risk markers in relation to long‐term complications in type 1 diabetes (2020) (5)
The angiotensin‐converting enzyme gene and its inhibition in diabetic nephropathy (1996) (5)
Autoregulation of Glomerular Filtration Rate in Patients with Diabetes (2000) (5)
Incident microalbuminuria and complement factor mannan‐binding lectin‐associated protein 19 in people with newly diagnosed type 1 diabetes (2017) (5)
An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. (2007) (5)
The blood‐retinal barrier permeability to fluorescein in juvenile diabetics treated with continuous subcutaneous insulin infusion (1985) (4)
Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study (2012) (4)
The effect of short‐term near‐normal blood glucose control on oscillatory potential and macular recovery time in insulin‐dependent diabetic patients with long‐standing metabolic dysregulation (1989) (4)
Surface Charge of Red Blood Cells in Insulin‐dependent Diabetic Patients with Incipient and Overt Nephropathy (1987) (4)
Commentary: microalbuminuria: past, present and glorious future. (2014) (4)
Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease (2020) (4)
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials (2018) (4)
Large Between-Patient Variability in eGFR Decline Before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy - A Post-Hoc Analysis From the SONAR Trial. (2021) (4)
Comparison of exposure response relationship of atrasentan between North American and Asian populations (2017) (4)
Converting enzyme-inhibition in diabetic nephropathy. (1989) (4)
Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin–angiotensin–aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients (2011) (4)
VITAMIN D LEVELS AND MORTALITY IN TYPE 2 DIABETES: PP.17.143 (2010) (3)
Renoprotective effects of renin-angiotensin-system inhibitors (2006) (3)
Abstract 426: The Diovan Reduction Of Proteinutria (Drop) Study: Albuminuria Response to High-Doses Of Valsartan in Type 2 Diabetes Mellitus (2006) (3)
Effect of ganglionic blockade on endogenous circulating pancreatic polypeptide, vasoactive intestinal polypeptide, substance P, neurotensin and noradrenaline in healthy controls and long-term insulin-dependent diabetic patients. (1986) (3)
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial (2021) (3)
Progression of renal disease (1994) (3)
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy. (2006) (3)
HYPERTENSION OPTIMAL TREATMENT (HOT) TRIAL. AUTHORS' REPLY (1998) (3)
Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. (2020) (3)
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial (2021) (3)
Prognosis in diabetic nephropathy: Authors' reply (1989) (3)
The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial. (2017) (3)
Effects of RAS inhibitors on diabetic retinopathy. (2015) (3)
The Course of Renal Function before and during Antihypertensive Treatment in Diabetic Nephropathy (1988) (3)
Reduction of urinary connective tissue growth factor by losartan in hypertensive Type 10 diabetic patients with diabetic nephropathy (2004) (2)
[Significant risk factors for development of microalbuminuria and diabetic nephropathy in patients with non-insulin-dependent diabetes]. (1998) (2)
[Pioneering research of Niels A. Lassen]. (2007) (2)
Renin angiotensin system blockade is effective in preventing microalbuminuria in hypertensive but not normotensive people with type 2 diabetes; further analysis of the DIRECT Programme (2010) (2)
Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients. (2020) (2)
ACE insertion/deletion genotypes and angiotensin II receptor blockade in diabetic nephropathy: is there a light at the end of the tunnel? (2003) (2)
The canosinase gene (CNDP1) is not a protection factor of diabetic nephropathy in type 1 diabetics (2006) (2)
Erratum to: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (2011) (2)
Telmisartan vs. enalapril in type 2 diabetes. (2005) (2)
Concentrations of von Willebrand factor in diabetes (1996) (2)
CGM-recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. (2022) (1)
ACE inhibition in diabetic nephropathy. (1990) (1)
NT-PROBNP AND HSTNT IMPROVE CARDIOVASCULAR RISK PREDICTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY OR CARDIOVASCULAR DISEASE OR BOTH (2014) (1)
Higher plasma advanced glycation endproducts levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study (2010) (1)
OF POST (2011) (1)
IMPACT OF TRANSCRIPTION-FACTOR 7-LIKE (TCF7L2) GENE-VARIANTS ON THE RESPONSE TO ANTI-HYPERGLYCAEMIC TREATMENT IN NON-OBESE PATIENTS WITH TYPE-2 DIABETES (T2DM) (2008) (1)
[Progress in the diagnosis and treatment of pneumocystis carinii pneumonia]. (1976) (1)
Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci (2015) (1)
ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia (2015) (1)
[Insulin pumps and treatment of diabetes]. (2003) (1)
40-LB: Association between Complement and Severe Retinal Complications in Type 1 Diabetes—An 18-Year Follow-Up Study (2019) (1)
Urinary sulphate excretion is a predictor for progression of diabetic nephropathy (2011) (1)
Antihypertensive drugs and diabetes mellitus. (1987) (1)
Going out to detect incipient diabetic nephropathy rather than waiting until it has supervened--a reversal in policy. (1996) (1)
[ACE inhibitors and AT-II antagonists--do they protect against renal disease?]. (2006) (1)
Tu-W19:4 Impact of metformin versus repaglinide on glycemic regulation and non-glycemic cardiovascular risk-markers in non-obese patients with type-2 diabetes (2006) (1)
MICROALBUMINURIA IN ESSENTIAL HYPERTENSION AND DIABETES MELLITUS. DISCUSSION (1996) (1)
SERUM PLACENTAL GROWTH FACTOR (PLGF) PREDICTS ALL-CAUSE AND CARDIOVASCULAR MORTALITY BUT NOT DETERIORATION OF KIDNEY FUNCTION IN TYPE 1 DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY: PP.6.254 (2010) (1)
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study (2020) (1)
[Albuminuria and glycemic control. The significance for mortality in non-insulin-dependent diabetes mellitus]. (1996) (1)
Submaximal dose of trandolapril in the COOPERATE trial (2003) (1)
Intensiveret multifaktoriel intervention hos patienter med type 2-diabetes mellitus og mikroalbuminuri: Steno-2-studietthe Steno-2 study (1999) (1)
The selective type A endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetes and nephropathy (2013) (1)
Years of Life Gained by Multifactorial Intervention in Patients with Type 2 Diabetes and Microalbuminuria - 21 Years Follow-Up on the Steno-2 Study (2016) (1)
Clinical trials report (2004) (1)
Plasma (cid:1) -Defensin Is Associated with Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients (2008) (1)
Effect of protein kinase C modulators on the leucocyte Na+/H+ antiport in Type 1 (insulin-dependent) diabetic subjects with albuminuria (1991) (0)
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia (2023) (0)
COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA (2018) (0)
Vitamin D levels and mortality in type 2 diabetes Running title: Vitamin D levels and mortality in type 2 diabetes (2010) (0)
Influence of Age/Gender/Race on the Efficacy of Ezetimibe/Simvastatin vs. Atorvastatin in Metabolic Syndrome Patients with Moderately High/High CHD Risk (2009) (0)
The `polypill' to reduce cardiovascular risk: proof of concept Data from the Steno-2 multifactorial intervention study in type 2 diabetes supports the `polypill' strategy to reduce cardiovascular risk (2004) (0)
Intensified Multifactorial Intervention in Type 2 Diabetes and Microalbuminuria Reduces End Stage Renal Disease and Mortality: 21 Years Follow-Up of the Steno-2 Study (2016) (0)
Atrasentan in patients with diabetes and chronic kidney disease – Authors' reply (2020) (0)
SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY DIABETIC NEPHROPTHY (2018) (0)
British Medical Journal (1874) (0)
Abstract: 582 ATTAINMENT OF SINGLE/DUAL TREATMENT LEVELS FOR LDL-C AND NON-HDL-C, APOB, OR HS-CRP IN PATIENTS WITH METABOLIC SYNDROME (MS): EZETIMIBE(E)/SIMVASTATIN(S) VS ATORVASTATIN(A) (2009) (0)
54 EFFECT OF ONE YEAR TREATMENT WITH INSULIN AND ORAL GLUCOSE-LOWERING AGENTS ON LIPID LEVELS IN NON-OBESE PATIENTS WITH TYPE 2-DIABETES (2011) (0)
Author's reply (1996) (0)
RNA oxidation and albuminuria in type 1 diabetes patients (2013) (0)
EURAGEDIC; European consortium for the genetics of diabetic nephropathy: strategy and first results. (2003) (0)
Pulse pressure partially explains the increased incident cardiovascular disease associated with inflammation in type 1 diabetes: a 12-yr follow-up study (2010) (0)
University of Groningen N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk Idzerda, (2018) (0)
Visit-to-Visit Variability of Clinical Risk Markers Is Predictive of Long-Term Complications in Type 1 Diabetes (2020) (0)
Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria (2023) (0)
Abstract: P966 EFFECT OF AGE/GENDER/RACE ON EZETIMIBE/SIMVASTATIN VS. ATORVASTATIN EFFICACY IN METABOLIC SYNDROME PATIENTS WITH MODERATELY HIGH/HIGH CHD RISK (2009) (0)
Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria (2002) (0)
Estimated GFR: Are There Limits to Its Utility?: Monitoring Kidney Function in Type 2 Diabetic Patients with Incipient and Overt Diabetic Nephropathy. Diabetes Care 29: 1024-1030, 2006. (2006) (0)
P295 COMPARISON OF METHODS FOR MEASURING LDL-CHOLESTEROL IN THE FASTING AND NONFASTING STATE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS (2010) (0)
Abstract: P947 EZETIMIBE/SIMVASTATIN (E/S) AND ATORVASTATIN (A) TREATMENT MODIFY APOB, LDL-C, AND NON-HDL-C CORRELATIONS IN METABOLIC SYNDROME (MS) PATIENTS AT MODERATELY HIGH RISK(MHR)/HIGH RISK(HR) FOR CHD (2009) (0)
Design of clinical trials in proteinuria and progressive renal disease (1992) (0)
[Salt restriction and blood pressure]. (1999) (0)
[Low birth weight--increased risk of diabetic nephropathies?]. (1996) (0)
908 EFFECTS OF ALISKIREN, IRBESARTAN AND THE COMBINATION ON URINARY LEVELS OF ANGIOTENSINOGEN AND RENIN IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND ALBUMINURIA (2012) (0)
Predictors of 10-year mortality in patients with type 2 diabetes mellitus (2000) (0)
Results from the ALTITUDE Trial (2012) (0)
Irbestartan is projected to be cost and life saving in the USA for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria (2003) (0)
PROactive study (2006) (0)
1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria (2020) (0)
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease (2022) (0)
270-OR: Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy (2020) (0)
[Diabetic angiopathies. Vascular function in poor metabolic regulation]. (1979) (0)
CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA (2003) (0)
Intensive therapy delayed microvascular complications in patients with type 2 diabetes mellitus and microalbuminuria (1999) (0)
Abstract 14182: Genome Wide Association Study for High Sensitive Cardiac Troponin T Levels Identifies a Novel Gene in Europeans With Type 1 Diabetes (2020) (0)
[HbA1 and type 2 diabetes--what is optimal?]. (2005) (0)
Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy (2002) (0)
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus (2016) (0)
Diabetes mellitus - clinical studies - 2 (2009) (0)
Abstract: P1308 EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN PATIENTS WITH HYPERCHOLESTEROLEMIA (HC) AND METABOLIC SYNDROME (METS) GROUPED BY PRESENCE OF ATHEROSCLEROTIC VASCULAR DISEASE (AVD) (2009) (0)
Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in PatientsWith Type 2 Diabetes andMicroalbuminuria An Irbesartan Microalbuminuria Type 2 Diabetes in Hypertensive Patients ( IRMA ) 2 substudy (2011) (0)
Effects of insulin administration by pumps on long-term diabetic complications (1985) (0)
Comparison of Treatment with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycaemia (HypoDeg): A Prospective, Randomized, Open-Label, Crossover Trial (2020) (0)
Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in type 2 diabetes (2016) (0)
Bone mineral density, kidney function and arterial stiffness in long-standing type 1 diabetic patients with or without diabetic nephropathy (2012) (0)
Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes (2018) (0)
Intensiv multifaktoriel behandling og mortalitet ved type 2- diabetes - Sekundærpublikation (2008) (0)
Effect of Metabolic Syndrome Factors and Insulin Resistance on Ezetimibe/Simvastatin and Atorvastatin Treatment Efficacy in Patients with Metabolic Syndrome and Moderately High/High CHD Risk (2009) (0)
Diabetic Nephropathy. In:Brenner & Rector's The Kidney, 10th editionElsevierISBN: 978-1-4557-4836-5, vol1, 1283-132. Rossing P, Fioretto p, Felt-Rasmussen B, Parving H-H. (2015) (0)
3141 Cataract and diabetes: A surgical model (1995) (0)
Chronic low-grade inflammation mediates the association between body mass index and pulse pressure in women with type 1 diabetes: a 20-yr longitudinal study (2008) (0)
Serum Uric Acid as aN ew Player in the Development of Diabetic Nephropathy (2011) (0)
EFFECTS OF DIETARY PROTEIN ON RENAL DISEASE. AUTHORS'REPLY (1997) (0)
Left ventricular function, mass, and volumes in type 1 diabetic patients – and relation to NT-proBNP (2008) (0)
Diabetic kidney disease: collaboration is the key (2012) (0)
SNP in GWAS hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes: Oral Presentation (2011) (0)
PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING (2005) (0)
[Splenectomy in chronic idiopathic thrombocytopenia]. (1977) (0)
University of Groningen Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight Koomen, (2018) (0)
[Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication]. (2005) (0)
Irbesartan treatment does not influence plasma levels of the advanced glycation end products CML and CEL in patients with type 2 diabetes and microalbuminuria. An IRMA2 substudy (2010) (0)
[New aspects in treatment and pathogenesis of mountain-sickness]. (1971) (0)
Endothelial dysfunction and low-grade inflammation precede the increase in urinary albumin excretion in type 1 diabetes: a 20-yr longitudinal study (2008) (0)
The 'polypill' to reduce cardiovascular risk : proof of concept : healthcare management (2005) (0)
237-OR: Beneficial Impact of Intensified Multifactorial Intervention on Stroke—The Steno-2 Study (2019) (0)
Diabetic nephropathy: Pathophysiology, hypertension and treatment. (1989) (0)
Acute Modulation of Renal Function in Microalbuminuric and Macroalbuminuric Insulin-Dependent Diabetic Patients (1988) (0)
Low-grade inflammation and endothelial dysfunction precede the increase in pulse pressure in type 1 diabetes: a 20-yr longitudinal study (2009) (0)
Higher plasma sRAGE levels are associated with incident cardiovascular morbidity and mortality as well as all-cause mortality in type 1 diabetes: a 12-yr follow-up study (2009) (0)
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria (2011) (0)
269-OR: Effect of Insulin Degludec on Frequency of Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia: The HypoDeg Trial (2020) (0)
Prevention and treatment of renal and cardiovascular disease in diabetes: new aspects (2013) (0)
131-OR: ADA Presidents’ Select Abstract: Effect of Insulin Degludec vs. Insulin Glargine U100 on Occurrence of Nocturnal Hypoglycemia Assessed by Nocturnal Plasma Glucose Profiles in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia (2021) (0)
PO22-724 IMPACT OF METFORMIN VERSUS REPAGLINIDE ON POSTPRANDIAL GLYCAEMIA AND PLASMA LIPOPROTEINS IN NON-OBESE PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) (2007) (0)
Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs (1996) (0)
Abstract: 31 EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN METABOLIC SYNDROME (MS) PATIENTS WITH HYPERCHOLESTEROLEMIA (HC) (2009) (0)
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. (2022) (0)
Abstract: P967 INFLUENCE OF METABOLIC SYNDROME (MS) FACTORS AND INSULIN RESISTANCE (IR) ON EZETIMIBE (E)/SIMVASTATIN (S) AND ATORVASTATIN (A) EFFICACY IN PATIENTS WITH MS AND MODERATELY HIGH (MH) OR HIGH (H) CHD RISK (2009) (0)
Determinants of progression in diabetic nephropathy with and without antihypertensive treatment (1992) (0)
Comparison of insulin degludec and glargine U100 in patients with type 1 diabetes prone to severe nocturnal hypoglycaemia (2020) (0)
Clinical trials report. angiotensin-converting enzyme inhibition in diabetes: above and beyond the beneficial effect of blood pressure? (2004) (0)
The Thioredoxin System in Diabetic Nephropathy (2008) (0)
Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/deletion polymorphism. Commentary (2006) (0)
Abstract 14369: Long-term Reduction in Coronary Artery Disease and Stroke With 7,8 Years of Intensified, Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria in the Steno-2 Study (2016) (0)
Issue Highlights. (2015) (0)
Genetic studies of diabetic nephropathy in three European populations (EURAGEDIC consortium): analyses of 14 candidate genes on chromosome 3q (2005) (0)
2-OR: Impact of N Terminal Pro B-Type Natriuretic Peptide and High Sensitivity Cardiac Troponin on the Prediction of Death and Cardiovascular Events in High-Risk Patients with Type 2 Diabetes (2020) (0)
Mannanbindende lektin og mortalitet hos patienter med type 2-diabetes--sekundaerpublikation (2009) (0)
Efficacy and Safety of Ezetimibe/Simvastatin vs. Atorvastatin in Patients with Hypercholesterolemia, Metabolic Syndrome, and Atherosclerotic Vascular Disease (2009) (0)
Prognosis in diabetic nephropathy. (1989) (0)
Monitoring kidney function in diabetic nephropathy (1989) (0)
Data from the Steno-2 multifactorial intervention study in type 2 diabetes supports the 'polypill' strategy to reduce cardiovascular risk (2004) (0)

This paper list is powered by the following services:

Hans Henrik D. Parving's Academic­Influence.com Rankings

Hans Henrik D. Parving's Degrees

Why Is Hans Henrik D. Parving Influential?

Hans Henrik D. Parving's Published Works

Published Works

Hans Henrik D. Parving's AcademicInfluence.com Rankings